Deadline Approaching: Boston Scientific Corporation (BSX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Core Viewpoint - Boston Scientific Corporation (BSX) is facing a securities fraud lawsuit due to disappointing financial results and misleading statements regarding its U.S. Electrophysiology (EP) segment growth [1] Financial Performance - On February 4, 2026, Boston Scientific reported fourth quarter and full year 2025 results, highlighting a decline in U.S. Electrophysiology sales and issuing fiscal 2026 guidance that fell below market expectations [1] - The company's stock price dropped by $16.12, or 17.6%, closing at $75.50 per share following the announcement [1] Lawsuit Details - The lawsuit alleges that Boston Scientific made materially false and misleading statements and failed to disclose adverse facts about its business and operations during the class period from July 23, 2025, to February 3, 2026 [1] - Specific allegations include unsustainable growth rates in the U.S. EP segment, new competition affecting market share, and misleading statements regarding the company's growth trajectory and business prospects [1]